Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Section 4 of 6

Clinical evidence

319 evidence topics · 39 sources

Study summaries

RINGSIDE part B

Objective
Location and study date
Registry status and dates for the combined Part A, Part B, and open-label extension record
Study characteristicQuoted record
Overall status“Active, not recruiting”
Study start (actual)“2021-09-01”
Primary completion (actual)“2025-12-03”
Study completion (estimated)“2026-12”
Number of locations“This study has 53 locations”
Study design
Eligibility criteria
Exclusion criteria for Parts A and B in the registry record
Treatment
Study outcomes
Rationale for using progression-free survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics, tumor characteristics, and prior therapy
Characteristic, n (%)Varegacestat (n=79)Placebo (n=77)
Median age (range), years“42.0 (18–66)”“39.0 (20–69)”
Male“26 (32.9)”“29 (37.7)”
Female“53 (67.1)”“48 (62.3)”
Premenopausal“36 (45.6)”“38 (49.4)”
Target tumor location: extra-abdominal“60 (75.9)”“49 (63.6)”
Target tumor location: intra-abdominal“19 (24.1)”“28 (36.4)”
Medical history of FAP“7 (8.9)”“8 (10.4)”
Median target tumor size per RECIST (range), mm“75.1 (18.0, 244.9)”“84.8 (21.3, 666.3)”
Any prior therapy“52 (65.8)”“60 (77.9)”
Prior surgery“24 (30.4)”“33 (42.9)”
Prior radiation therapy“8 (10.1)”“12 (15.6)”
Prior systemic therapy“43 (54.4)”“46 (59.7)”
Prior systemic therapies: 0 lines“36 (45.6)”“31 (40.3)”
Prior systemic therapies: 1 line“25 (31.6)”“22 (28.6)”
Prior systemic therapies: 2 or more lines“18 (22.8)”“24 (31.2)”
Premenopausal women as a proportion of female participants
CharacteristicVaregacestat (n=79)Placebo (n=77)
Premenopausal, n/N of female participants (%)“36/53 (67.9)”“38/48 (79.2)”
Efficacy results
RINGSIDE phase 3 trial outcomes table
OutcomeVAR (n=79)PBO (n=77)HR (95% CI) or Difference; P value
Median PFS (95% CI), radiographic, months“NE (NE, NE)”“24.9 (13.8, NE)”“0.16 (0.07, 0.38); P<0.0001”
Confirmed ORR, n (%)“44 (55.7)”“7 (9.1)”“P<0.0001”
TV change (cm3) at Week 24, LS mean (SE)“-109.6 (40.64)”“122.8 (42.72)”“-232.4 (57.39); P<0.0001”
WPI (pain) change at Week 12, LS mean (SE)“-2.24 (0.27)”“0.18 (0.27)”“-2.42 (0.37); P<0.0001”
Median best % change in TV (not alpha-controlled)“-83.4”“11.3”
Landmark progression-free survival rates at 1 and 2 years
Objective response, time to response, and best overall response
OutcomeVaregacestat (n=79)Placebo (n=77)
Objective response rate, n (%) [95% CI]“44 (55.7) [44.1, 66.9]”“7 (9.1) [3.7, 17.8]”
Time to objective response (months), median (range)“8.2 (2.6–28.0)”“16.7 (8.1–30.2)”
Duration of response (months), median (95% CI), Kaplan-Meier estimate“NE (NE, NE)”“NE (NE, NE)”
Complete response (CR)“3 (3.8)”“1 (1.3)”
Partial response (PR)“41 (51.9)”“6 (7.8)”
Stable disease (SD)“32 (40.5)”“59 (76.6)”
Progressive disease (PD)“0”“10 (13.0)”
Not available“3 (3.8)”“1 (1.3)”
Health-related quality of life and patient-reported outcomes
Safety results
Adverse events reported in 25% or more of either arm, ASCO 2026 presentation
Adverse event (MedDRA preferred term), n (%)Varegacestat any gradeVaregacestat grade 3+Placebo any gradePlacebo grade 3+
Any adverse event“79 (100)”“45 (57)”“70 (91)”“13 (17)”
Diarrhea“65 (82)”“8 (10.1)”“21 (27)”“0”
Fatigue“35 (44)”“1 (1.3)”“18 (23)”“2 (2.6)”
Rash“34 (43)”“2 (2.5)”“9 (12)”“0”
Nausea“28 (35)”“0”“20 (26)”“0”
Cough“27 (34)”“0”“4 (5)”“0”
Hypophosphatemia“27 (34)”“1 (1.3)”“2 (3)”“0”
Alopecia“26 (33)”“0”“3 (4)”“0”
Dry mouth“24 (30)”“0”“5 (7)”“0”
Hair color changes“20 (25)”“0”“0”“0”
Pruritus“20 (25)”“0”“4 (5)”“0”
Rash maculo-papular“20 (25)”“1 (1.3)”“1 (1)”“0”
Most common treatment-emergent adverse events reported in 20% or more of either arm, ESMO 2026 safety poster
Adverse event (MedDRA preferred term), n (%)Varegacestat any gradeVaregacestat grade ≥3Placebo any gradePlacebo grade ≥3
Any adverse event“79 (100)”“45 (57)”“70 (91)”“13 (17)”
Diarrhea“65 (82)”“8 (10)”“21 (27)”“0”
Fatigue“35 (44)”“1 (1)”“18 (23)”“2 (2.6)”
Rash“34 (43)”“2 (3)”“9 (12)”“0”
Nausea“28 (35)”“0”“20 (26)”“0”
Cough“27 (34)”“0”“4 (5)”“0”
Hypophosphatemia“27 (34)”“1 (1)”“2 (3)”“0”
Alopecia“26 (33)”“0”“3 (4)”“0”
Dry mouth“24 (30)”“0”“5 (7)”“0”
Hair color changes“20 (25)”“0”“0”“0”
Pruritus“20 (25)”“0”“4 (5)”“0”
Rash maculo-papular“20 (25)”“1 (1)”“1 (1)”“0”
ALT increase“18 (23)”“3 (4)”“4 (5)”“0”
AST increase“18 (23)”“2 (3)”“2 (3)”“0”
Amenorrhea“17 (22)”“0”“2 (3)”“0”
Upper respiratory tract infection“17 (22)”“0”“5 (7)”“0”
Vomiting“16 (20)”“0”“6 (8)”“0”
Frequently reported adverse events as grouped terms, with median time to first onset
Adverse event, n (%)Varegacestat all gradesVaregacestat median time to onset (days)Varegacestat grade ≥3Placebo all gradesPlacebo median time to onset (days)Placebo grade ≥3
Diarrhea“65 (82.3)”“14.0”“8 (10.1)”“21 (27.3)”“21.0”“0”
Rash (grouped term)“56 (70.9)”“24.0”“4 (5.1)”“13 (16.9)”“69.0”“0”
Fatigue (grouped term)“46 (58.2)”“27.5”“1 (1.3)”“24 (31.2)”“19.0”“2 (2.6)”
Hair follicle AEs (grouped term)“32 (40.5)”“59.0”“2 (2.5)”“3 (3.9)”“70.0”“0”
Cough (grouped term)“31 (39.2)”“16.0”“1 (1.3)”“5 (6.5)”“198.0”“0”
Nausea“28 (35.4)”“8.0”“0”“20 (26.0)”“7.5”“0”
Hypophosphatemia“27 (34.2)”“29.0”“1 (1.3)”“2 (2.6)”“49.5”“0”
Upper respiratory infection (grouped term)“27 (34.2)”“46.0”“0”“6 (7.8)”“136.5”“0”
Dry mouth“24 (30.4)”“13.0”“0”“5 (6.5)”“8.0”“0”
Hair color changes“20 (25.3)”“60.5”“0”“0”“0”
Ovarian toxicity (grouped term; percentage of the whole population)“20 (25.3)”“56.5”“0”“2 (2.6)”“41.5”“0”
Select adverse events of interest by grade, including squamous cell carcinoma and keratoacanthoma
Adverse event of interestVaregacestat grade 1Varegacestat grade 2Varegacestat grade 3Placebo grade 1Placebo grade 2Placebo grade 3
Diarrhea“43.0%”“29.1%”“10.1%”“23.4%”“3.9%”
Rash (grouped terms)“36.7%”“29.1%”“5.1%”“14.3%”“2.6%”
Ovarian toxicity“25.3%”“2.6%”
Squamous cell carcinoma and keratoacanthoma“1.3%”“6.3%”“1.3%”“1.3%”
Elevated liver enzymes (ALT or AST grade 2 or higher)“3.8%”“3.8%”“2.6%”
Adverse events leading to dose interruption
Preferred term, n (%)Varegacestat (n=79)Placebo (n=77)
Diarrhea“9 (11.4)”“1 (1.3)”
Fatigue“6 (7.6)”“0”
Rash“6 (7.6)”“0”
Vomiting“5 (6.3)”“1 (1.3)”
ALT increased“4 (5.1)”“2 (2.6)”
Pyrexia“4 (5.1)”“1 (1.3)”
Study limitations
Summary
  • Part B results are available only as an ASCO 2026 meeting abstract and oral presentation, ESMO 2026 presentations, and Immunome press releases and investor presentations. The abstract states that it “does not include a full text component”. The ClinicalTrials.gov record (primary completion December 3, 2025; status active, not recruiting) lists no posted results, and no registry protocol or statistical analysis plan is available for comparison with the reported analyses. The study was “sponsored/funded by Immunome and Ayala Pharmaceuticals, Inc.”.
  • The comparator is placebo. No trial has compared varegacestat with nirogacestat, the approved gamma secretase inhibitor; Immunome's cross-trial response rate chart states that “no head-to-head clinical trial has been conducted”.
  • Crossover to the open-label extension was allowed from either arm at progression, and the open-label extension is ongoing. Median exposure was 20.3 months with varegacestat and 11.1 months with placebo, so cumulative adverse event frequencies are compared over unequal exposure.
  • At the October 7, 2025 data cutoff, 7 of 79 varegacestat participants and 29 of 77 placebo participants had a PFS event; median PFS was not estimable and median duration of response was not reached with varegacestat, which limits the precision of the hazard ratio and of the 2-year landmark estimates.
  • The ASCO presentation labels a “Post-hoc subgroup analysis to evaluate patients with poor prognosis”; the subgroups shown include age 30 years or younger, CTNNB1 mutation, and baseline tumor size above 10 cm, and the abstract states only that PFS “consistently favored VAR in all subgroups analyzed”.
  • Baseline imbalances include intra-abdominal target tumors (24.1% with varegacestat and 36.4% with placebo), any prior therapy (65.8% and 77.9%), and prior surgery (30.4% and 42.9%); the placebo arm's target tumor size range extends to 666.3 mm.
  • Dose reductions due to adverse events occurred in 80% of varegacestat participants (to 0.9 mg in 60 and to 0.6 mg in 36), and dose interruptions in 65%. The efficacy results therefore reflect a 1.2 mg starting dose with frequent reduction, and the dose intensity actually delivered has not been reported.
  • The symptom, pain domain, and physical function analyses are exploratory, with nominal p values. Completion declined over time: at week 48, pain and symptom data were available for 37 varegacestat and 27 placebo participants, against 52 and 55 at week 12. The PROMIS Physical Function baseline was “redefined post hoc”. Characteristic adverse events (diarrhea in 82% versus 27%, alopecia in 33% versus 4%, hair color changes in 25% versus 0%) may have allowed participants to infer their assignment, which could bias patient-reported outcomes in a double-blind trial.
  • Figures differ between sources. The PFS hazard ratio's 95% CI is 0.07 to 0.38 in the abstract and slides and 0.071 to 0.375 in Immunome releases. ORR is 55.7% versus 9.1% in the abstract and slides and 56% versus 9% in releases. Placebo discontinuation due to adverse events is 7% in the abstract, ASCO slides, and safety poster and 6% in the primary results poster. Premenopausal women are 45.6% of the varegacestat arm in one table and 67.9% of its female participants in another. Rash is 43% as a preferred term and 70.9% as a grouped term. Death is reported as “No deaths due to adverse events” in the ESMO safety poster and as “There were no deaths on study” in the investor presentations. Ovarian toxicity resolved in 55% overall but in all 8 participants with follow-up off treatment. Week 48 PROMIS Physical Function is reported as +3.90 versus −3.04 in the ESMO press release, while the presentation, using the redefined baseline, reports a difference of +6.54.

RINGSIDE part A

Objective
Location and study date
Registry dates and study identifier
FieldQuoted record
First posted“2021-05-04”
Study start (actual)“2021-09-01”
Other study ID“AL-DES-01”
Study design
Eligibility criteria
Registry inclusion criteria for Part A

“Inclusion Criteria Part A:” (opens the source at this quote in a new tab)

“At least 18 years of age (inclusive) at the time of signing the informed consent form (ICF).” (opens the source at this quote in a new tab)

“Disease progression, assessed locally by the investigator, defined as having at least one of the following:” (opens the source at this quote in a new tab)

“Unidimensional growth of desmoid tumor(s) by ≥10%, using the sum of the largest diameters of target lesion(s), within 18 months of the screening MRI” (opens the source at this quote in a new tab)

“Having desmoid tumor-related pain that is not adequately controlled with nonopioid medication” (opens the source at this quote in a new tab)

“At least 1 measurable lesion amenable to volume measurements by MRI at screening” (opens the source at this quote in a new tab)

“Treatment naïve subjects for whom, in the opinion of the investigator, the IP is deemed appropriate, OR” (opens the source at this quote in a new tab)

“Recurrent/refractory disease following at least one line of therapy (including surgery, radiation, or systemic therapy)” (opens the source at this quote in a new tab)

“Must be able to swallow whole capsules with no GI condition affecting absorption; nasogastric or G-tube administration is not allowed.” (opens the source at this quote in a new tab)

Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registry enrollment
FieldQuoted record
Enrollment (actual)“198”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographic and clinical characteristics by dose arm
Characteristic1.2 mg once daily (n = 14)2 mg intermittent (n = 14)4 mg intermittent (n = 14)All doses (N = 42)
Age, years, mean (SD)“42.1 (11.32)”“37.8 (14.76)”“39.9 (13.99)”“39.9 (13.23)”
Female, No. (%)“11 (78.6)”“9 (64.3)”“11 (78.6)”“31 (73.8)”
Women of childbearing potential, No. (%)“9 (64.3)”“7 (50.0)”“7 (50.0)”“23 (54.8)”
Intra-abdominal tumor at screening, No. (%)“3 (21.4)”“4 (28.6)”“3 (21.4)”“10 (23.8)”
Tumor volume at baseline by BICR, cm3, mean (SD)“83.93 (92.280)”“189.17 (368.846)”“166.91 (211.038)”“146.05 (242.664)”
CTNNB1 mutation, No. (%)“8 (57.1)”“4 (28.6)”“8 (57.1)”“20 (47.6)”
APC mutation, No. (%)“2 (14.3)”“5 (35.7)”“2 (14.3)”“9 (21.4)”
Prior systemic therapy, No. (%)“9 (64.3)”“13 (92.9)”“7 (50.0)”“29 (69.0)”
Prior surgery, No. (%)“7 (50.0)”“8 (57.1)”“4 (28.6)”“19 (45.2)”
Prior radiation therapy, No. (%)“1 (7.1)”“2 (14.3)”“1 (7.1)”“4 (9.5)”
Unidimensional tumor growth by ≥10% within 18 months of screening, No. (%)“11 (78.6)”“14 (100.0)”“10 (71.4)”“35 (83.3)”
Tumor-related pain not adequately controlled with nonopioid medicine, No. (%)“5 (35.7)”“5 (35.7)”“5 (35.7)”“15 (35.7)”
Median age, performance status, and median baseline tumor volume
Characteristic1.2 mg once daily (n=14)All doses (N=42)
Age (years), median (min, max)“44.0 (24, 61)”“38.5 (19, 72)”
ECOG performance status 0, n (%)“14 (100.0)”“35 (83.3)”
ECOG performance status 1, n (%)“0”“7 (16.7)”
Intra-abdominal tumor at initial diagnosis, n (%)“5 (35.7)”“12 (28.6)”
Extra-abdominal tumor at initial diagnosis, n (%)“9 (64.3)”“30 (71.4)”
Tumor volume at baseline (cm3), median (min, max)“46.30 (1.4, 244.9)”“65.10 (1.4, 1270.3)”
Efficacy results
Tumor response by BICR per RECIST v1.1 during the randomized trial
Response1.2 mg once daily (n = 14)2 mg intermittent (n = 14)4 mg intermittent (n = 14)All doses (N = 42)
Partial response, No. (%)“5 (35.7)”“3 (21.4)”“3 (21.4)”“11 (26.2)”
Stable disease, No. (%)“7 (50.0)”“6 (42.9)”“10 (71.4)”“23 (54.8)”
Progressive disease, No. (%)“0”“2 (14.3)”“0”“2 (4.8)”
Not available, No. (%)“2 (14.3)”“3 (21.4)”“1 (7.1)”“6 (14.3)”
Objective response 95% CI“12.8 to 64.9”“4.7 to 50.8”“4.7 to 50.8”“13.9 to 42.0”
Time to objective response, weeks, median (min, max)“30.00 (17.3, 40.9)”“40.29 (38.3, 41.0)”“51.00 (40.3, 53.7)”“40.29 (17.3, 53.7)”
Tumor response by BICR per RECIST v1.1 in the randomized trial and open-label extension combined
ResponseOriginal 1.2 mg once daily (n = 14)Original 2 mg intermittent (n = 14)Original 4 mg intermittent (n = 14)All (N = 42)
Complete response, No. (%)“0”“1 (7.1)”“1 (7.1)”“2 (4.8)”
Partial response, No. (%)“8 (57.1)”“6 (42.9)”“8 (57.1)”“22 (52.4)”
Objective response, No. (%)“8 (57.1)”“7 (50.0)”“9 (64.3)”“24 (57.1)”
Objective response 95% CI“28.9 to 82.3”“23.0 to 77.0”“35.1 to 87.2”“41.0 to 72.3”
Time to objective response, weeks, median (min, max)“37.71 (17.3, 65.1)”“40.57 (28.1, 101.6)”“63.00 (40.3, 121.3)”“51.50 (17.3, 121.3)”
Duration of response, weeks, median (95% CI)“NE (46.1 to NE)”“NE (24.9 to NE)”“NE (NE to NE)”“NE (NE to NE)”
Objective response rate from 43% to 78% across subgroups
SubgroupResponders, No. (%)
Age ≤40 years (n=22) vs. >40 years (n=14)“13 (59) vs. 10 (71)”
Tumor size <70 mm (n=18) vs. ≥70 mm (n=14)“13 (72) vs. 9 (64)”
Prior lines of therapy: 0 (n=11), 1 (n=16), or 2+ (n=9)“6 (55), 10 (63), 7 (78)”
Intra-abdominal (n=9) vs. extra-abdominal (n=27)“4 (44) vs. 19 (70)”
APC (n=7) vs CTNNB1 (n=19) mutation“3 (43) vs. 13 (68)”
Objective response and duration of response by subgroup as of January 6, 2025
SubgroupORR, n (%)DOR, weeks, median (min, max)
All MRI-evaluable patients (n=37)“24 (65)”“58.9 (12.1, 120.6)”
Age ≤40 years (n=22)“13 (59)”“66.1 (22.1, 110.0)”
Age >40 years (n=15)“11 (73)”“37.1 (12.1, 120.6)”
Tumor size <70 mm (n=19)“10 (53)”“52.1 (22.1, 99.0)”
Tumor size ≥70 mm (n=18)“14 (78)”“78.4 (12.1, 120.6)”
Prior lines of therapy 0 (n=11)“6 (55)”“79.8 (22.1, 95.9)”
Prior lines of therapy 1 (n=13)“9 (69)”“37.1 (12.1, 120.6)”
Prior lines of therapy 2+ (n=13)“9 (69)”“56.0 (12.1, 110.0)”
Intra-abdominal (n=10)“5 (50)”“46.1 (12.1, 99.0)”
Extra-abdominal (n=27)“19 (70)”“61.9 (12.1, 120.6)”
APC mutation (n=8)“4 (50)”“55.4 (12.1, 66.1)”
CTNNB1 mutation (n=19)“13 (68)”“79.6 (22.1, 120.6)”
CTNNB1 S45F (n=3)“2 (67)”“31.0 (24.9, 37.1)”
CTNNB1 T41A (n=5)“2 (40)”“88.2 (55.9, 120.6)”
CTNNB1 other (n=11)“9 (82)”“82.0 (22.1, 110.0)”
Objective response and median best change in tumor volume in the evaluable population
Response1.2 mg QD dose (n=12)All doses (n=36)
Objective response rate (CR + PR), n (%)“9 (75%)”“23 (64%)”
Complete response, n (%)“0 (0%)”“2 (6%)”
Partial response, n (%)“9 (75%)”“21 (58%)”
Stable disease, n (%)“3 (25%)”“12 (33%)”
Progressive disease, n (%)“0 (0%)”“1 (3%)”
Disease control rate, n (%)“12 (100%)”“35 (97%)”
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events during the randomized trial by dose arm
Treatment-emergent adverse event, No. (%)1.2 mg once daily (n = 14)2 mg intermittent (n = 14)4 mg intermittent (n = 14)All doses (N = 42)
Any event“14 (100.0)”“14 (100.0)”“14 (100.0)”“42 (100.0)”
Treatment-related“14 (100.0)”“13 (92.9)”“14 (100.0)”“41 (97.6)”
Grade ≥3“5 (35.7)”“7 (50.0)”“4 (28.6)”“16 (38.1)”
Treatment-related grade ≥3“3 (21.4)”“3 (21.4)”“3 (21.4)”“9 (21.4)”
Serious“1 (7.1)”“4 (28.6)”“1 (7.1)”“6 (14.3)”
Leading to dose reduction“6 (42.9)”“0”“5 (35.7)”“11 (26.2)”
Leading to interruption“11 (78.6)”“5 (35.7)”“7 (50.0)”“23 (54.8)”
Leading to study drug withdrawal“4 (28.6)”“2 (14.3)”“0”“6 (14.3)”
Diarrhea“14 (100.0)”“8 (57.1)”“12 (85.7)”“34 (81.0)”
Nausea“7 (50.0)”“4 (28.6)”“10 (71.4)”“21 (50.0)”
Fatigue“7 (50.0)”“5 (35.7)”“6 (42.9)”“18 (42.9)”
Alopecia“7 (50.0)”“2 (14.3)”“4 (28.6)”“13 (31.0)”
Dry skin“7 (50.0)”“1 (7.1)”“5 (35.7)”“13 (31.0)”
Hypophosphatemia“6 (42.9)”“5 (35.7)”“2 (14.3)”“13 (31.0)”
Headache“1 (7.1)”“5 (35.7)”“6 (42.9)”“12 (28.6)”
Stomatitis“7 (50.0)”“2 (14.3)”“3 (21.4)”“12 (28.6)”
Amenorrhea“4 (28.6)”“3 (21.4)”“4 (28.6)”“11 (26.2)”
AST increased“4 (28.6)”“4 (28.6)”“3 (21.4)”“11 (26.2)”
Hot flush“3 (21.4)”“4 (28.6)”“4 (28.6)”“11 (26.2)”
Vomiting“3 (21.4)”“4 (28.6)”“4 (28.6)”“11 (26.2)”
Adverse events of special interest by dose arm, appendix table
Event, No. (%)1.2 mg once daily (n = 14)2 mg intermittent (n = 14)4 mg intermittent (n = 14)All doses (N = 42)
One or more adverse events of special interest“6 (42.9)”“5 (35.7)”“5 (35.7)”“16 (38.1)”
Amenorrhea“3 (21.4)”“3 (21.4)”“4 (28.6)”“10 (23.8)”
Premature menopause“0”“0”“1 (7.1)”“1 (2.4)”
Elevated liver enzymes (CTCAE grade ≥2)“2 (14.3)”“2 (14.3)”“0”“4 (9.5)”
Squamous cell carcinoma of skin“1 (7.1)”“0”“0”“1 (2.4)”
Treatment-emergent adverse events in the randomized trial and open-label extension combined
Treatment-emergent adverse event, No. (%)Original 1.2 mg once daily (n = 14)Original 2 mg intermittent (n = 14)Original 4 mg intermittent (n = 14)All doses (N = 42)
Grade ≥3“6 (42.9)”“11 (78.6)”“6 (42.9)”“23 (54.8)”
Treatment-related grade ≥3“4 (28.6)”“6 (42.9)”“4 (28.6)”“14 (33.3)”
Serious“1 (7.1)”“6 (42.9)”“1 (7.1)”“8 (19.0)”
Leading to dose reduction“7 (50.0)”“3 (21.4)”“8 (57.1)”“18 (42.9)”
Leading to interruption“11 (78.6)”“8 (57.1)”“9 (64.3)”“28 (66.7)”
Leading to study drug withdrawal“4 (28.6)”“4 (28.6)”“1 (7.1)”“9 (21.4)”
Diarrhea“14 (100.0)”“9 (64.3)”“12 (85.7)”“35 (83.3)”
Nausea“8 (57.1)”“5 (35.7)”“10 (71.4)”“23 (54.8)”
Fatigue“8 (57.1)”“6 (42.9)”“8 (57.1)”“22 (52.4)”
Hypophosphatemia“7 (50.0)”“5 (35.7)”“3 (21.4)”“15 (35.7)”
Stomatitis“7 (50.0)”“5 (35.7)”“3 (21.4)”“15 (35.7)”
Cough“3 (21.4)”“5 (35.7)”“6 (42.9)”“14 (33.3)”
Rash“1 (7.1)”“7 (50.0)”“6 (42.9)”“14 (33.3)”
Upper respiratory tract infection“3 (21.4)”“2 (14.3)”“6 (42.9)”“11 (26.2)”
Study limitations
Summary
  • RINGSIDE Part A was an open-label, randomized, dose-finding phase II study with 14 participants in each of three varegacestat dose regimens and no placebo or active comparator arm; the investigators describe it as having “small sample sizes and no placebo or active comparator arm”. The primary endpoint was safety; change in tumor volume at week 16 by BICR was the secondary endpoint, and RECIST v1.1 objective response rate was exploratory.
  • The sample size was powered for the change in tumor volume from baseline within each regimen (12 participants per regimen, 85% power), so comparisons between regimens are descriptive: the LS mean reduction at week 16 was statistically significant for 1.2 mg once daily (–39.8%) and not for the 2 mg (–21.7%) or 4 mg (–17.8%) intermittent regimens. The efficacy analysis set (37 MRI-evaluable participants, 88.1%) excluded participants without measurable disease at baseline or a valid MRI at week 4 or later.
  • The open-label extension switched all 29 continuing participants (69.0%) to 1.2 mg once daily between week 36 and week 76, so long-term results by original dose arm (confirmed ORR 57.1%, 50.0%, and 64.3%) reflect both the randomized regimen and later exposure to 1.2 mg once daily. Participants could continue varegacestat after progression by BICR with sponsor approval.
  • Response rates differ by data cutoff and analysis population: an evaluable-population ORR of 75% for 1.2 mg once daily and 64% for all doses (April 10, 2024), an intention-to-treat ORR of 55% for all doses in the 10-K, and a confirmed ORR of 57.1% among all 42 participants as of January 6, 2025. Two abstracts with the April 10, 2024 cutoff report different median times on treatment (25.4 and 23.1 months), and two interim abstracts report grade 3 drug-related TEAEs in 26.2% (January 3, 2023 cutoff) and in 10 of 42 participants (24%).
  • Subgroup analyses were post hoc, pooled across dose regimens, and limited to subgroups with at least 5 participants; the investigators state that “The sample sizes in each subgroup are relatively small”. The T2-weighted signal and exposure-response analyses were exploratory.
  • Patient-reported outcomes were not analyzed because of “limited data availability and small sample sizes”. Ovarian toxicity had not resolved at last follow-up in 6 of 12 affected women. The study was sponsored by Immunome and Ayala Pharmaceuticals.

CA002-001

Objective
Location and study date
Registry status, dates, and sites
Study characteristicQuoted record
Protocol number“CA002-001”
Sponsor“Bristol-Myers Squibb”
Overall status“Terminated”
Reason stopped“(Non-safety reason, business objectives have changed)”
Study start“2013-11”
Primary completion“2016-03”
Study completion“2016-03”
United States site“Usc/Norris Comprehensive Cancer Center”
Site cities“Los Angeles”; “Parkville”; “Vancouver”; “Toronto”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using maximum tolerated dose as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-related adverse events of all grades by dose level
Adverse event1.2 mg once daily (N = 6)1.5 mg once daily (N = 7)Arm A total (N = 24)All patients (N = 36)
Diarrhoea“6 (100)”View highlighted excerpt for this quote“6 (86)”View highlighted excerpt for this quote“18 (75)”View highlighted excerpt for this quote“26 (72)”View highlighted excerpt for this quote
Nausea“4 (67)”View highlighted excerpt for this quote“5 (71)”View highlighted excerpt for this quote“15 (63)”View highlighted excerpt for this quote“22 (61)”View highlighted excerpt for this quote
Vomiting“2 (33)”View highlighted excerpt for this quote“4 (57)”View highlighted excerpt for this quote“12 (50)”View highlighted excerpt for this quote“16 (44)”View highlighted excerpt for this quote
Hypophosphataemia“6 (100)”View highlighted excerpt for this quote“4 (57)”View highlighted excerpt for this quote“16 (67)”View highlighted excerpt for this quote“23 (64)”View highlighted excerpt for this quote
Decreased appetite“2 (33)”View highlighted excerpt for this quote“1 (14)”View highlighted excerpt for this quote“8 (33)”View highlighted excerpt for this quote“13 (36)”View highlighted excerpt for this quote
Hypokalaemia“3 (50)”View highlighted excerpt for this quote“2 (29)”View highlighted excerpt for this quote“7 (29)”View highlighted excerpt for this quote“10 (28)”View highlighted excerpt for this quote
Rash“3 (50)”View highlighted excerpt for this quote“2 (29)”View highlighted excerpt for this quote“8 (33)”View highlighted excerpt for this quote“11 (31)”View highlighted excerpt for this quote
Pruritus“0”View highlighted excerpt for this quote“2 (29)”View highlighted excerpt for this quote“6 (25)”View highlighted excerpt for this quote“9 (25)”View highlighted excerpt for this quote
Fatigue“2 (33)”View highlighted excerpt for this quote“4 (57)”View highlighted excerpt for this quote“10 (42)”View highlighted excerpt for this quote“16 (44)”View highlighted excerpt for this quote
Study limitations
Summary
  • CA002-001 was an open-label, nonrandomized phase 1 dose-escalation study without a comparator arm in 36 participants with advanced solid tumours (24 in the once-daily arm and 12 in the twice-weekly arm). One participant (3%) had desmoid fibromatosis, so the study provides no estimate of efficacy in desmoid tumors; that participant “did not have documented disease progression before study entry” and was treated at 1.5 mg once daily, a dose above the 1.2 mg once-daily dose used in RINGSIDE.
  • Six participants received 1.2 mg once daily, and five of them were evaluable for dose-limiting toxicity. The median duration of treatment was 5.6 weeks (range 0.9 to 57.9 weeks), which limits the assessment of adverse events that emerge with longer exposure.
  • The study was “terminated early for business reasons”, and the maximum tolerated dose of the twice-weekly schedule was not established. The registry lists the reason as a “Non-safety reason, business objectives have changed” and shows no posted results.
  • Tumour response was assessed by the investigator per RECIST 1.1, with no central review reported. All analyses were descriptive.
  • The eligibility criteria required ECOG performance status 0 to 1, and the baseline characteristics report one participant (3%) with baseline WHO performance status 2.
  • Bristol-Myers Squibb sponsored and funded the study, and six authors were Bristol-Myers Squibb employees and stockholders.

AL102-501

Objective
Location and study date
Registry status, dates, and site
Study characteristicQuoted record
Protocol number“AL102-501”
Sponsor“Immunome, Inc.”
Overall status“Completed”
Study start (actual)“2024-11-11”
Primary completion (actual)“2024-12-30”
Study completion (actual)“2025-05-07”
First posted“2024-11-07”
Last update posted“2025-05-11”
Site“Celerion”; “Tempe”
Study design
Registry design fields
Study characteristicQuoted record
Phase“Phase 1”
Intervention model“Single Group Assignment”
Masking“None (Open Label)”
Primary purpose“Other”
Keywords“Drug-Drug Interaction”; “Pharmacokinetics”
Eligibility criteria
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
Study characteristicQuoted record
Enrollment (actual)“22”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • AL102-501 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2024-12-30, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the effect of itraconazole on varegacestat exposure is unknown from public sources.
  • The study is an open-label, single-group, fixed-sequence design in 22 healthy participants aged 18 to 55 years, with women limited to those of non-childbearing potential. Each participant received a single dose of varegacestat alone and then with itraconazole, so the results apply to single-dose exposure in healthy adults.
  • The registry record does not state the varegacestat dose given.

AL102-502

Objective
Location and study date
Registry status, dates, and site
Study characteristicQuoted record
Protocol number“AL102-502”
Sponsor“Immunome, Inc.”
Overall status“Completed”
Study start (actual)“2025-02-24”
Primary completion (actual)“2025-04-08”
Study completion (actual)“2025-05-06”
First posted“2025-03-03”
Last update posted“2025-09-24”
Site“Celerion”; “Tempe”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using placebo-corrected QTc change as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
Study characteristicQuoted record
Enrollment (actual)“32”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • AL102-502 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2025-04-08, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the effect of varegacestat on the QTc interval is unknown from public sources.
  • The study gave a single oral dose of varegacestat to 32 healthy participants aged 18 to 55 years, with women limited to those of non-childbearing potential. The registry record does not state the dose. In the phase 1 study of BMS-986115, the median accumulation ratio after once-daily dosing at 1.2 mg was 3.66, so exposure after a single dose is lower than exposure after 15 days of once-daily dosing.
  • Moxifloxacin, the positive control, was given open label, and blinding applied to varegacestat and placebo only.

AL102-503

Objective
Location and study date
Registry status, dates, and sites
Study characteristicQuoted record
Protocol number“AL102-503”
Sponsor“Immunome, Inc.”
Overall status“Completed”
Study start (actual)“2025-03-07”
Primary completion (actual)“2025-11-05”
Study completion (actual)“2026-03-06”
First posted“2025-02-24”
Last update posted“2026-03-10”
Sites“Orlando Clinical Research Center”; “The Texas Liver Institute”
Study design
Registry design fields
Study characteristicQuoted record
Phase“Phase 1”
Intervention model“Single Group Assignment”
Masking“None (Open Label)”
Primary purpose“Other”
Eligibility criteria
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
Study characteristicQuoted record
Enrollment (actual)“35”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • AL102-503 is known only from its registry record. The record lists the study as “Completed”, with study completion on 2026-03-06, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so varegacestat exposure in hepatic impairment is unknown from public sources.
  • The registry gives the actual enrollment as 35 participants but not their distribution across the healthy, mild, moderate, and severe hepatic impairment groups. Enrollment of the severe group (Child-Pugh C) was planned only “if appropriate”, contingent on data from the first three groups.
  • The design is open label with a single oral dose, and the registry record does not state the dose.

AL102-504

Objective
Location and study date
Registry status, dates, and site
Study characteristicQuoted record
Protocol number“AL102-504”
Sponsor“Immunome, Inc.”
Overall status“Completed”
Study start (actual)“2025-02-25”
Primary completion (actual)“2025-03-11”
Study completion (actual)“2025-03-26”
Last update posted“2025-09-26”
Site“Frontage Laboratories, Inc.”; “Secaucus”
Study design
Registry design fields
Study characteristicQuoted record
Phase“Phase 1”
Intervention model“Single Group Assignment”
Masking“None (Open Label)”
Primary purpose“Other”
Eligibility criteria
Treatment
Study outcomes
Rationale for using mass balance recovery as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
Study characteristicQuoted record
Enrollment (actual)“6”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • AL102-504 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2025-03-11, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the routes of elimination and the metabolite profile of varegacestat are unknown from public sources.
  • The study enrolled 6 healthy men aged 18 to 55 years and gave a single dose of approximately 100 µCi of [14C]varegacestat, so it provides no data in women, in patients with desmoid tumors, or at steady state.

VAR-505

Objective
Location and study date
Registry status, dates, and site
Study characteristicQuoted record
Protocol number“VAR-505”
Sponsor“Immunome, Inc.”
Overall status“Recruiting”
Study start (actual)“2026-05-21”
Primary completion (estimated)“2027-05”
Study completion (estimated)“2027-05”
First posted“2026-05-27”
Last update posted“2026-10-29”
Site“Celerion, Inc.”; “Tempe”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated enrollment
Study characteristicQuoted record
Enrollment (estimated)“44”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • VAR-505 is known only from its registry record. The record lists the study as “Recruiting”, with an actual start on 2026-05-21 and estimated primary completion in 2027-05, and no results are available.
  • The registry record names a reference formulation and test formulations A, B, and C without stating their strengths or composition, so the relationship between the test capsules and the capsules used in RINGSIDE or proposed for marketing cannot be determined from the record.
  • The study enrolls healthy adults aged 18 to 55 years under fasting conditions, with an estimated enrollment of 44 participants.